drugset / Trial / NCT00928447

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

NCT00928447

Phase 2 Completed 22 enrolled Halozyme Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the effect and safety of rHuPH20 or placebo for the prevention and treatment of skin allergic reaction to nickel. The study drug and placebo will be administered by intradermal injection.

Timeline

Start
2009-06-23
Primary completion
2009-09-13
Completion
2009-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject rHuPH20 Protein / enzyme biologic 3000 iu Other